Literature DB >> 3034150

Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro.

M Baba, S Shigeta.   

Abstract

One of the plant extracts, glycyrrhizin (GL) was investigated for its antiviral action on varicella-zoster virus (VZV) in vitro. When human embryonic fibroblast (HEF) cells were treated with GL after inoculation of virus (post-treatment), the average 50%-inhibitory dose (ID50) for five VZV strains was 0.71 mM, and the selectivity index (ratio of ID50 for host-cell DNA synthesis to ID50 for VZV replication) was 30. GL was also effective against VZV replication when HEF cells were treated 24 h before the inoculation (pretreatment). Furthermore, at a concentration of 2.4 mM GL inactivated more than 99% of virus particles within 30 min at 37 degrees C. In combination with other anti-herpes drugs (acyclovir, adenine arabinoside, bromovinyldeoxyuridine, and phosphonoformate) or human native beta-interferon, GL had an additive or slightly synergistic effect on VZV replication. The mechanism of anti-VZV action is still unclear. We postulate that GL inhibits the penetration, uncoating or release of virus particles.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034150     DOI: 10.1016/0166-3542(87)90025-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  26 in total

1.  Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection.

Authors:  Y Da Nagao; M Sata; H Suzuki; K Tanikawa; K Itoh; T Kameyama
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

2.  The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope.

Authors:  Shinji Harada
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

3.  Glycyrrhizic Acid Prevents Sepsis-Induced Acute Lung Injury and Mortality in Rats.

Authors:  Hongyu Zhao; Min Zhao; Yu Wang; Fengchun Li; Zhigang Zhang
Journal:  J Histochem Cytochem       Date:  2015-09-18       Impact factor: 2.479

4.  Glycyrrhizic Acid Attenuates Sepsis-Induced Acute Kidney Injury by Inhibiting NF-κB Signaling Pathway.

Authors:  Hongyu Zhao; Min Zhao; Yu Wang; Fengchun Li; Zhigang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-24       Impact factor: 2.629

5.  Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency.

Authors:  Gretchen L Bentz; Angela J Lowrey; Dustin C Horne; Vy Nguyen; Austin R Satterfield; Tabithia D Ross; Abigail E Harrod; Olga N Uchakina; Robert J McKallip
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

6.  Antiviral effects of saikosaponins on human coronavirus 229E in vitro.

Authors:  Pei-Win Cheng; Lean-Teik Ng; Lien-Chai Chiang; Chun-Ching Lin
Journal:  Clin Exp Pharmacol Physiol       Date:  2006-07       Impact factor: 2.557

7.  Antiviral effect of diammonium glycyrrhizinate and lithium chloride on cell infection by pseudorabies herpesvirus.

Authors:  Xiuwen Sui; Jiechao Yin; Xiaofeng Ren
Journal:  Antiviral Res       Date:  2009-10-30       Impact factor: 5.970

8.  Antiviral activity of glycyrrhizin against hepatitis C virus in vitro.

Authors:  Yoshihiro Matsumoto; Tomokazu Matsuura; Haruyo Aoyagi; Mami Matsuda; Su Su Hmwe; Tomoko Date; Noriyuki Watanabe; Koichi Watashi; Ryosuke Suzuki; Shizuko Ichinose; Kenjiro Wake; Tetsuro Suzuki; Tatsuo Miyamura; Takaji Wakita; Hideki Aizaki
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

9.  Comparative study to evaluate the anti-viral efficacy of Glycyrrhiza glabra extract and ribavirin against the Newcastle disease virus.

Authors:  Muhammad Ovais Omer; Waleed Hassan Almalki; Imran Shahid; Shahzada Khuram; Imran Altaf; Saeed Imran
Journal:  Pharmacognosy Res       Date:  2014-01

10.  Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial.

Authors:  Youichi Yanagawa; Masatsune Ogura; Eita Fujimoto; Satoshi Shono; Eriya Okuda
Journal:  Curr Ther Res Clin Exp       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.